Hypoxia-induced reprogramming to RPE stem cells

描述(申请人提供)：在尾目动物和无尾两栖动物中，视网膜再生的一个主要组成部分是RPE向神经视网膜的转分化。但哺乳动物的再生是有限的，这使得它们容易受到视网膜损伤和致盲疾病的影响。最近的研究发现，在培养的人RPE中存在RPE干细胞(RPESC)。这些RPESC表现出不受限制的增殖和分化潜能，非常类似于间充质干细胞(MSC)，后者与RPE具有共同的神经上皮来源。虽然RPESC分化为表达神经元标志物，但不能诱导出Rho等感光性标志物。因此，这些RPESC可能不是哺乳动物RPE转分化为光感受器的中间产物。我们对成年小鼠RPE的培养进行了检测，以寻找具有RPESC分化能力的细胞，但我们未能鉴定这种细胞。然而，我们发现，具有RPESC特性的细胞可以通过低氧依赖的途径高效而稳定地从RPE(IRPESC)诱导出来，类似于所描述的维持和诱导MSC的途径。缺氧会导致RPE损伤，并与新生血管和AMD有关。这种iRPESC重编程途径的关键是将缺氧诱导因子1a(HIF1a)超诱导到足以结合和激活Oct4干细胞基因启动子的阈值。Oct4反过来诱导Dnmt1，使细胞周期沉默，阻断细胞周期蛋白依赖性激酶抑制剂，导致不受限制的增殖。这些iRPESC耐缺氧，重要的是，与人类RPESC不同，它们可以分化为Rho+细胞-事实上，这种向Rho+细胞的分化比胚胎干细胞或诱导的多能干细胞更有效。此外，iRPESC不会经历典型的上皮-间充质转化(EMT)，这为RPE在细胞扩增时保留RPE表型提供了可能性。由于AMD等致盲疾病突出表现为功能性RPE和光感受器的丧失，iRPESC经历光感受器分化和抵抗EMT启动的表型丧失的能力表明了该细胞独特的治疗潜力。在这个R21提案的两年时间里，我们的目标是在分子水平上研究iRPESC重编程途径。这些研究的目的是为实验设计提供基础，以优化iRPESC的光感受器分化，并在iRPESC扩增的同时保持功能性RPE表型，以便在未来我们可以开始在移植实验中测试分化的iRPESC的有效性。分子分析的第二个要点是确定最终可用于体内检测iRPESC的途径标记，并了解未来可能用于刺激原位RPE产生iRPESC的因素。

DESCRIPTION (provided by applicant): In urodeles and anurans a major component of retinal regeneration is transdifferentiation of RPE to neural retina. But regeneration is limited in mammals, leaving them susceptible to retinal injury and blinding diseases. Recent studies identified a population of RPE stem cells (RPESC) among cultures of human RPE. These RPESC show unrestricted proliferation and their differentiation potential closely resembled mesenchymal stem cells (MSC), which share a common neuroepithelial origin with RPE. Although RPESC differentiated to express neuronal markers, they failed to induce photoreceptor markers such as RHO. Thus, these RPESC may not represent an intermediate in transdifferentiation of mammalian RPE into photoreceptors. We examined cultures of adult mouse RPE for cells with the differentiation capacity of RPESC, but we failed to identify such cells. However, we found that cells with properties of RPESC can be efficiently and stably induced from RPE (iRPESC) through a hypoxia-dependent pathway, similar to that described for maintenance and induction of MSC. Hypoxia causes RPE damage and is linked to neovascularization and AMD. Key to this iRPESC reprogramming pathway is superinduction of hypoxia inducible factor 1a (Hif1a) to a threshold sufficient to bind and activate the Oct4 stem cell gene promoter. Oct4 in turn induces Dnmt1 which silences cell cycle blocking cyclin dependent kinase inhibitors leading to unrestricted proliferation. These iRPESC are resistant to hypoxia, and importantly, as opposed to human RPESC, they differentiate into Rho+ cells-indeed this differentiation to Rho+ cells is more efficient than seen with embryonic stem cells or induced pluripotent stem cells. Furthermore, iRPESC do not undergo the typical epithelial-mesenchymal transition (EMT) seen when RPE are placed in culture, providing the potential for retaining an RPE phenotype as the cells are expanded. Because blinding diseases such as AMD are highlighted by loss of both functional RPE and photoreceptors, the ability of the iRPESC to undergo photoreceptor differentiation and to resist EMT-initiated loss of phenotype suggest a unique therapeutic potential for the cells. During the two year period of this R21 proposal, we aim to investigate the iRPESC reprogramming pathway on a molecular level. The purpose of these studies is to provide a foundation for experiments designed to optimize photoreceptor differentiation from iRPESC and to maintain a function RPE phenotype as iRPESC are expanded, so in the future we can begin testing the effectiveness of the differentiated iRPESC in transplantation experiments. A second point of this molecular analysis is to identify pathway markers that can ultimately be used for detection of iRPESC in vivo, and to understand factors that might be used in the future to stimulate iRPESC generation from RPE in situ.